Genetics of rheumatoid arthritis contributes to biology and drug discoveryYukinori Okada, René E. M. Toes, Di Wu et al.|Nature|2013Cited by 2.5k
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation studyJesse J. Swen, Roelof Bosch, Cathelijne H. van der Wouden et al.|The Lancet|2023Cited by 508
Clinical pharmacokinetics of tyrosine kinase inhibitorsNielka P. van Erp, Henk‐Jan Guchelaar, Hans Gelderblom|Cancer Treatment Reviews|2009Cited by 498
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M. Henricks, Jan H.M. Schellens, Arnold Baars et al.|The Lancet Oncology|2018Cited by 419